Trading volume for Zynerba Pharma CS was 1,380K in the last trading session. Trading volume was up 180.07% over the stocks average daily volume.
Traders are a little more bearish on Zynerba Pharma CS of late as indicated by the motion in short interest. The stock realized a rise in short interest between September 29, 2017 and October 13, 2017 of 27.35%. Short interest increased from 2,227,100 to 2,836,313 over that timeframe. With short interest at 2,836,313 and short average daily volume at 797,348, the short-interest ratio is 4.0 and the percentage of shorted shares was 0.21% on October 13.
These firms have modified their investment in ZYNE. Mirae Asset Global Investments Co., Ltd. grew its holdings by buying 35,442 shares an increase of 11.7% from 06/30/2017 to 09/30/2017. Mirae Asset Global Investments Co., Ltd. claims 338,552 shares with a value of $2,830,000. The value of the position overall is down by 45.0%. Citigroup Inc reduced its investment by shedding 622 shares a decrease of 55.4%. Citigroup Inc now controls 500 shares worth $4,000. The total value of its holdings decreased 78.9%.
California State Teachers Retirement System downsized its stake by shedding 900 shares a decrease of 4.5% in the quarter. California State Teachers Retirement System owns 19,300 shares valued at $161,000. The value of the position overall is down by 53.1%. As of the end of the quarter Oz Management Lp had bought a total of 9,600 shares growing its holdings by 100.0%. The value of the total investment in Zynerba Pharma CS went from $193,000 to $161,000 decreasing 16.6% quarter to quarter.
On October 1, 2017 Roth Capital released research on ZYNE stating a rating of “Buy” and projecting a price target of $15.00.
Equity analyst Canaccord Genuity raised the price target on September 29 boosting the projection from $9.00 to $15.00 and stated a “Buy” rating. September 29 investment analysts at Oppenheimer Holdings reiterated a “Hold” rating on the stock.
September 28 investment analysts at Cantor Fitzgerald left the stock rating at “Hold” with a current price target of $4.00.
The company is so far trading down since yesterday’s close of 13.45. The P/E ratio is currently N/A and the market value is 171.58M. In the latest earnings report the EPS was $-2.59 with 13.55M shares currently outstanding.
Zynerba Pharmaceuticals, Inc., launched on January 31, 2007, is a specialty pharmaceutical company. The Company is involved in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001..